Latest News — Page 89

However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.

Benefit-risk assessment is a crucial step in evaluating the safety and efficacy of medical products. Quantitative benefit-risk assessment (qBRA) is a set of techniques that can help drug and medical device developers and regulators to evaluate the benefit-risk balance of medical products. This report outlines five main steps for developing qBRAs. The first step is to identify the research question and specify the role of external experts. The second step involves developing a formal analysis model by selecting benefit and […]

Introduction: The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction (LVEF ≤40%) starting April 1, 2022. Yet, the Pharmaceutical Benefits Advisory Committee (PBAC) decided in November 2022 not to endorse Empagliflozin for treating CHF in patients with a left ventricular ejection fraction over 40%. They based their decision on the high unmet clinical need and the economic model’s failure to capture the disease’s progressive […]

Iberian Healthcare Collaboration: Spain & Portugal Unite for Health Technology Assessments!

A new report highlights the pervasive market failure in the antibiotics space and proposes a globally aligned, value-based, fully-delinked pull incentive to future-proof antibiotic innovation. The mechanism would involve payers paying manufacturers a pre-specified subscription fee, based on the value of the antibiotic, over a pre-specified period, regardless of the volume of antibiotics used. The report suggests that the size of a global pull incentive should be calculated by aggregating revenue from all countries where the product is sold, with […]

Some items listed as REQUIRING PRE-AUTHORISATION: Forxiga (Dapagliflozin) Byetta (Exenatide) Janumet (Metformin/Sitagliptin) Onglyza (Saxagliptin) Januvia (Sitagliptin) Galvus (Vildagliptin) + including Metformin combinations Liptruzet (Atorvastatin/Ezetimibe) Ezetrol (Ezetimibe) Inegy(Ezetimibe/Simvastatin) Details regarding the EXCLUDED ITEMS: Trulicity (Dulaglutide) Jardiance (Empagliflozin) Xultophy (Insulin Degludec and Liraglutide) Soliqua (Insulin Glargine and Lixisenatide) Victoza (Liraglutide) Synjardy (Metformin and Empagliflozin) Ozempic (Semaglutide)

The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.

Abu Dhabi Stem Cells Center (ADSCC), a subsidiary of PureHealth, has been named a centre of excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi. The centre provides specialised and distinguished programmes with a high level of expertise and multidisciplinary resources, allowing it to conduct advanced medical procedures in specific clinical areas and conducting complex researches to provide the highest levels of care. The centre will provide an integrated and specialised range of surgical and […]

DARWIN EU®, a network for data analysis and real-world interrogation, has successfully completed its first year of operation. The network has onboarded ten data partners and initiated four studies using real-world data from across Europe to better understand diseases, populations, and the uses and effects of medicines. DARWIN EU® generates real-world evidence to support the decision-making of EMA scientific committees and national competent authorities in EU Member States throughout regulatory processes. The network plans to onboard ten additional data partners […]

The World Health Organization expressed concern about the disruption of essential health services for chronic disease management due to the COVID-19 pandemic. A study done in Indonesia’s Malang district, showed concerns regarding restrictions on movement and access to health services for patients with chronic conditions, such as those at high risk for cardiovascular disease. However, fears about disruptions to the supply of essential medicines were largely unfounded, as primary health centers and private suppliers had supplies of all cardiovascular medicines […]

The study examines the impact of import verification fees on local pharmaceutical production in Uganda. The findings suggest that the policy has been effective in promoting local production, with an 8.2% increase in production capacity observed. The study also highlights the challenges faced by the local industry, including limited access to raw materials, high operating costs, and inadequate quality control equipment. The authors recommend that the government provide necessary support to the local industry, including policies to protect local manufacturers […]

A health technology assessment (HTA) of treatment regimens for patients with multiple myeloma in Norway was done. The goals of treatment are to prolong life, achieve a strong response without side effects, and maintain quality of life. The article discusses the uncertainty surrounding the results of a health economic analysis of treatment regimens for multiple myeloma. The uncertainty is due to reliance on component network meta-analysis and lack of access to patient level data. The methods used to derive underlying […]

Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by […]

ICER has released a White Paper on Health Equity. This paper measures the impact of health technology assessment (HTA) on equity, and suggests approaches to leverage HTA to advance health equity for racial, ethnic, and socially disadvantaged groups. When decision-makers evaluate data to inform pricing and insurance coverage, they must consider the implications for health equity. They have taken a close look at every step of our work to assess if we and other HTA groups can make improvements and […]

NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer. They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.